A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Mirza, M. R.
Bjorge, L.
Marme, F.
Christensen, R. DePont
Gil-Martin, M.
Auranen, A.
Ataseven, B.
Rubio, M. J.
Salutari, V.
Lund, B.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
